BCHMY
Bachem Holding AG, together with its subsidiaries, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide. It engages ...
TickerTrends Research on Bachem Holding AG (BCHMY)
主要经营地
Switzerland
详细生意模式
Peptide Contract Development & Manufacturing Organization (CDMO) with clinical pipeline segment (CMC Development) converting to recurring commercial revenue. GLP-1 validated peptides accelerate broader peptide therapeutics pipeline growth. CMC Development +29.7% YoY to CHF304M vs Commercial API +5% to CHF343.4M shows transition from single-class to multi-class manufacturing bottleneck.
护城河
🟢 Core infrastructure for structural peptide expansion with manufacturing bottleneck moat; differentiated peptide capabilities; Building K expansion adds 1-ton annual capacity; US $250M 2026-2030 investment
估值水平
EV/EBITDA 23.89x
EV/Market Cap
$5.0B / $5.0B
网络观点
Mispriced as GLP-1 play when actually diversified peptide CDMO with CMC pipeline converting to recurring commercial revenue with multi-year lag; forecasts beat H1 2026 consensus
AI观点
Bachem positioned well for peptide expansion but premium valuation (24x EBITDA) already prices in significant growth; Building K ramp and US expansion provide technical credibility but execution risk on capacity utilization remains material